**You are receiving this message as a VCVP/VAVP enrolled provider contact of the Immunization Program**

**Beginning August 1st, MenQuadfi will replace Menactra as the only meningococcal A, C, W, Y conjugate vaccine (MenACWY) supplied by Sanofi.**

**Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 | MMWR**

"ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination with MenACWY for persons aged ≥ 2 months at increased risk for meningococcal disease."

**State-supplied Meningococcal A, C, W, Y vaccines now include:**
- MenQuadfi (Sanofi) – Approved for 2 years and older (state-supplied through age 64)
- Menveo (GSK) – Approved for 2 months through 55 years

**To be removed August 1st:**
- Menactra (Sanofi) – Approved for 9 months through 55 years

- MenQuadfi will replace Menactra in practice catalogs automatically on August 1st.
- This change does not impact practices that previously selected Menveo for Oct 2021 – Sept 2022 through the vaccine choice process.
- Use the existing inventory of Menactra at your practice before ordering MenQuadfi.
- Practices in need of MenACYW vaccine for patients younger than age 2 can make a special request of Menveo by e-mailing AHS.VDHImmunizationProgram@vermont.gov, or leaving a comment in VIMS. See the MenACWY Vaccine Recommendation by Age and Risk Factor for guidance on when a request for Menveo is appropriate.

Any questions about this change can be sent to AHS.VDHImmunizationProgram@vermont.gov.